ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.

Trial Details

NCT ID

NCT07109531

Phase

PHASE3

Sponsor

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

ASKC202+ Limertinib
Pemetrexed + Cisplatin /Carboplatin

Locations (sample)

Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Willing and able to provide signed and dated informed consent;
Patients at least 18 years of age;
Locally advanced or metastatic non-small cell lung cancer (NSCLC);
Objective disease progression following prior EGFR-TKI therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →